Valneva SE (VALN) Income towards Parent Company (2021 - 2026)
Valneva SE (VALN) posted Income towards Parent Company of -$27.7 million for Q1 2026, up 52.41% sequentially from -$58.3 million in Q4 2025, and down 342.51% YoY from $11.4 million in Q1 2025.
Analysis
Valneva SE (VALN) Income towards Parent Company (2021 - 2026) Analysis & Trends
Valneva SE has reported Income towards Parent Company for 6 years, with the latest figure at -$27.7 million in Q1 2026.
- Quarterly Income towards Parent Company fell 342.51% year-over-year to -$27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$154.9 million (down 135.6% YoY) and the FY2025 annual result came in at -$134.1 million, down 1029.61% from the prior year.
- Income towards Parent Company grew to -$27.7 million in Q1 2026 per VALN's latest filing, from -$58.3 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $94.1 million in Q3 2022 and troughed at -$156.3 million in Q2 2022.
- A 5-year average of -$22.5 million and a median of -$24.1 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company surged 516.53% in 2024, then sank 379.79% in 2025.
- Over 5 years, Income towards Parent Company stood at -$57.5 million in 2022, then jumped by 53.39% to -$26.8 million in 2023, then surged by 54.66% to -$12.1 million in 2024, then tumbled by 379.79% to -$58.3 million in 2025, then soared by 52.41% to -$27.7 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$27.7 million, -$58.3 million, and -$56.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Valneva SE | 581.90 Mn | 440.64 Mn | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.20 |
| Mar 31, 2026 | 0.21 |
| Dec 31, 2025 | 0.34 |
| Sep 30, 2025 | 0.30 |
| Jun 30, 2025 | 0.08 |
| Mar 31, 2025 | 0.06 |
| Dec 31, 2024 | -0.11 |
| Sep 30, 2024 | -0.08 |
| Jun 30, 2024 | -0.18 |
| Mar 31, 2024 | 0.46 |
| Dec 31, 2023 | 0.25 |
| Sep 30, 2023 | 0.27 |
| Jun 30, 2023 | 0.13 |
| Mar 31, 2023 | 0.14 |
| Dec 31, 2022 | 0.33 |
| Sep 30, 2022 | 151.65 Mn |
| Jun 30, 2022 | -151.43 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | 201.46 Mn |
| Sep 30, 2021 | -185.83 Mn |